All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
The MPN Hub were pleased to speak to Aaron Gerds, Cleveland Clinic Taussig Cancer Institute, Cleveland, US, during the 61st American Society of Hematology (ASH) meeting in Orlando, US. We asked: Could pacritinib represent a new efficacious treatment for patients with myelofibrosis who have failed ruxolitinib?
Aaron Gerds discusses the PAC203 study that evaluated the efficacy of the JAK inhibitor, pacritinib, in patients with myelofibrosis and low platelet counts, he talks about the patient characteristics, the optimal dose, safety, response rates and overall outcomes of patients. He also discusses the place of pacritinib in the treatment pathway and its effect on patient outcomes.
Is pacritinib safe and efficacious for patients with MF who failed ruxolitinib?
Your opinion matters
Subscribe to get the best content related to MPN delivered to your inbox